Next generation gynecological cancer diagnostics market growth

Market Overview:
The Next Generation Gynecological Cancer Diagnostics Market is anticipated to grow at a significant growth rate, and the analysis period is 2022-2028, considering the base year as 2021.
Gynecological cancer is cancer that develops in the female reproductive organs. Cancer is always named after the part of the body in which it first appears. Gynecological cancers can develop in any part of a woman’s pelvis, that is, the area below the stomach and between the hip bones. Gynecological cancers include cancers of the cervix, ovary, uterus, vagina and vulva. The most common gynecological cancer is ovarian cancer. The development of innovative techniques for the diagnosis of gynecological cancer, such as quantitative polymerase chain reaction (qPCR) and multiplexing, next-generation sequencing, lab-on-a-chip (LOAC) and reverse transcription-chain reaction by polymerase (RT-PCR), and microarray, has resulted from technological advancement.

Read more:
https://introspectivemarketresearch.com/reports/next-generation-gynecological-cancer-diagnostic-market/

Market dynamics:
Driver:
During the period of analysis, the main factor stimulating the development of new generation gynecological cancer diagnostics has been the increase in the number of cases of gynecological cancers. Breast cancer is the most commonly diagnosed cancer in women worldwide, while cervical cancer is the fourth most common cancer in women, with approximately 604,000 new cases in 2020. In 2020 , low- and middle-income countries will account for about 90% of the population. the estimated 342,000 deaths from cervical cancer. HIV-positive women are six times more likely to develop cervical cancer than HIV-negative women, with HIV accounting for about 5% of all cervical cancer cases. Additionally, HIV causes a disproportionate number of cervical cancers in young women worldwide.

Opportunities:
30-50% of cancers can be prevented by avoiding risk factors and implementing evidence-based prevention strategies. Cancer can be reduced by early detection, as well as proper treatment and care for cancer patients. Many cancers can be cured if detected early and treated appropriately. Several governments have taken action to control the spread of non-communicable diseases. Cardiovascular diseases, cancer, chronic respiratory diseases, diabetes and other non-communicable diseases are thought to account for over 60% of all deaths in India.

Request a sample report:
https://introspectivemarketresearch.com/request/16267

Market segmentation
Next Generation Gynecological Cancer Diagnostics Market Segmentation Analysis
By technology, the next-generation sequencing segment is expected to grow at the highest CAGR over the forecast period. Next-generation sequencing has proven to be a valuable tool for gaining deeper and more accurate insight into the molecular underpinnings of individual tumors. Compared to traditional approaches, NGS has the potential to have a significant impact on the field of oncology due to its accuracy, sensitivity and speed. Since NGS can test many genes in a single test, it eliminates the need for multiple tests to find the causative mutation, thus supporting segment development.
• qPCR and multiplexing
• Next Generation Sequencing
• DCA and RT-PCR
• Other

By function, the companion diagnostics segment is expected to dominate the next-generation gynecological cancer diagnostics market over the forecast period. Companion diagnostics help healthcare professionals determine a patient’s response to a specific agent to improve cancer patient outcomes and improve personalized medicine. It also contributes to the curtailment of rising healthcare expenses by restricting the consumption of drugs to those who will benefit significantly from them, thus furthering the expansion of the segment over the projected period.
• Companion diagnostics
• Therapeutics & Monitoring
• Prognosis
• Cancer screening
• Risk analysis

By application, the biomarker development segment is expected to lead the development of the next-generation gynecological cancer diagnostics market. Patients with the same cancer type previously received the same treatment, but research has shown that tumors even within the same cancer type have distinct characteristics. Doctors are increasingly relying on cancer biomarkers to learn more about a patient’s tumor and predict which treatment will be most effective against their specific cancer. Biomarkers can be used to personalize treatment for each patient, thereby reducing treatment costs.
• Development of biomarkers
• CTC analysis
• Proteomic analysis
• Epigenetic analysis
• Others

Next Generation Gynecological Cancer Diagnostics Market Regional Analysis
The North American region is expected to dominate the next-generation cancer diagnostics market over the forecast period, owing to the rising prevalence of ovarian cancer. According to the American Cancer Society, approximately 19,880 women in the United States will be newly diagnosed with ovarian cancer in 2022. The Society also estimated that 12,810 women will die from ovarian cancer.

The European region is expected to have the second highest share of the next-generation cancer diagnostics market over the analysis period. Cervical cancer is expected to account for 2.5% of cancer cases (excluding non-melanoma skin cancers) identified in women in 2020, and 2.4% of all deaths from cancer in women. Cervical cancer is the 11th most common cancer in women and the 12th most common cause of cancer death among them.

Next-generation cancer diagnostics market in Asia-Pacific region is expected to grow at the highest CAGR over the analysis period. According to the ICO/IARC Information Center on HPV and Cancer, every year 123,907 women in India are diagnosed with cervical cancer and 77,348 die from it. Cervical cancer is the second most common disease among women in India and the second most common cancer among women aged 15-44.
• North America (United States, Canada, Mexico)
• Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, rest of APAC)
• Middle East and Africa (Turkey, Saudi Arabia, Iran, United Arab Emirates, Africa, Rest of MEA)
• South America (Brazil, Argentina, Rest of South Africa)

Top Key Players Covered in Next Generation Gynecological Cancer Diagnostics Market
• Agilent Technologies (California, USA)
• ARUP Laboratories (California, USA)
• BGI Genomics (Shenzhen, China)
• CENTOGENE NV (Rostock, Germany)
• F. Hoffmann-La Roche SA (Basel, Switzerland)
• Fulgent Genetics (California, USA)
• Illumina Inc. (California, USA)
• Invitae Corporation (California, USA)
• Konica Minolta Inc. (Tokyo, Japan)
• Laboratory Corporation of America Holdings (California, USA)
• Myriad Genetics (Utah, USA)
• OPKO Health Inc. (Florida, USA)
• QIAGEN AG (Germany)
• Quest Diagnostics Incorporated (USA)
• Thermo Fisher Scientific Inc. (USA) and other major players.

Key Industry Developments in the Next Generation Gynecological Cancer Diagnostics Market
In May 2022, Agilent Technologies Inc. announced that its pharmDx PD-L1 IHC 22C3, code SK006, had received EU CE-IVD approval for use in cervical cancer. PD-L1 IHC 22C3 pharmDx may help identify patients with cervical cancer who may benefit from treatment with KEYTRUDA® (pembrolizumab).

In February 2021, QIAGEN and INOVIO Pharmaceuticals announced a new collaborative framework agreement to develop liquid biopsy-based companion diagnostic solutions* based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies.
In July 2020, Thermo Fisher Scientific signed a CDx agreement with Chugai Pharmaceutical and requested the Ministry of Health, Labor and Welfare (MHLW) to expand the use of the Oncomine Dx target test in Japan.

Find out before you buy:
https://introspectivemarketresearch.com/request/16267

Contents
Chapter 1 Introduction
1.1 Research objectives
1.2 Research methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market definition
1.4.2 Answers to key questions
1.5 Market Segmentation

Chapter 2: Executive Summary

Chapter 3: Growth Opportunities by Segment
3.1 By technology
3.2 By function
3.3 By application

Chapter 4: Market Landscape
4.1 Porter’s Five Forces Analysis
4.1.1 Bargaining power of the supplier
4.1.2 Threat of new entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining power between buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Constraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle analysis
4.5 Technology roadmap
4.6 Regulatory landscape
4.7 SWOT analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the impact of Covid-19
4.10.1 Impact on the overall market
4.10.2 Impact on the supply chain
4.10.3 Impact on Major Manufacturers
4.10.4 Impact on pricing
To be continued.

Buy this report @
https://introspectivemarketresearch.com/checkout/?user=1&_sid=16267

Related reports:
https://introspectivemarketresearch.com/reports/non-small-cell-lung-cancer-market/
https://introspectivemarketresearch.com/reports/cancer-tissue-diagnostics-market/

Contact us:
Introspective market research
3001S King Drive,
Chicago, Illionis
60616 United States
Phone number: +1-773-382-1047
Email: [email protected]

About Us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consultancy dedicated to helping our clients grow and achieve successful market impact. Our team at IMR is ready to help our clients grow their business by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in using big data and advanced analytics to show the big picture of market trends. We help our clients think differently and build a better future for all of us. We are a technology driven research company, we analyze extremely large datasets to uncover deeper insights and provide conclusive insights.

This press release was published on openPR.